Immunotherapy Archives

Anastasiia Slynko neobe therapeutics cancer

Startup Scout 19 Oct 2022

Neobe Therapeutics breaks down tumor defenses with bacteria

Many cancer patients cannot benefit from cancer immunotherapy because their tumors are protected from the immune system. Neobe Therapeutics’ bacterial therapy is designed to strip the tumors of their protective barriers. The immune system is very good at fighting tumors, and cancer immunotherapies are often able to supercharge our natural defenses to great effect. However, […]

October 19, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 12 Oct 2022

Agreement signed to advance therapy for autoimmune disease

HanAll Biopharma’s licensed partner, Harbour BioMed, has signed an exclusive sublicense agreement with CSPC NBP Pharmaceutical Co., Ltd for an advanced inhibitor. The agreement is for HanAll’s neonatal Fc receptor (FcRn) inhibitor batoclimab which is one of the most advanced being developed in Greater China. The companies say it has the potential to become a […]

October 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 11 Oct 2022

Accelerated application for drug to help immunodeficiency submitted by Pharming

A marketing authorization application (MAA) has been submitted by Dutch company Pharming Group, to the European Medicines Agency (EMA) for a rare, primary immunodeficiency in adults and adolescents 12 years and older. Activated phosphonide 3-kinase delta syndrome (APDS), first discovered in 2013, is caused by genetic variants in either one of two identified genes known […]

October 11, 2022 - 4 minutesmins - By Liza Laws

Anastasiia Slynko biotech investment 744x368 1

In Depth 11 Oct 2022

The biggest private biotech investments in September 2022

The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […]

October 11, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 3 Oct 2022

Estrella and TradeUP merge to become publicly traded company

Estrella Biopharma, Inc. and TradeUP Acquisition Corp. have entered into a definitive business combination agreement that will result in Estrella becoming a publicly listed company. Upon closing of the transaction, TradeUP will be renamed Estrella Immunopharma, Inc. Estrella Biopharma is a preclinical-stage biopharmaceutical company developing CD19-targeted ARTEMIS T-cell therapies under certain license agreements with the […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

CAR-T cell therapy, cancer therapy, cell therapy

News and Trends 27 Sep 2022

Bioheng Biotech has positive CAR-T cell therapy results published in academic journal

Positive results from a phase 1 clinical study of RD13-01, an anti-CD7 universal CAR-T therapy product, have been published in reputable academic journal, Cell Research. China-based Bioheng Biotech Co. Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy made the announcement today (September 27). The results published with the title of ‘CD7-targeted allogeneic CAR-T […]

September 27, 2022 - 3 minutesmins - By Liza Laws

kai pinkernell glycostem nk cell therapy

Interview 27 Sep 2022

Natural killer cells: a thriving frontier in allogeneic cell therapy

Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could usher in off-the-shelf cancer immunotherapies. Since their first approvals in 2017, chimeric antigen receptor (CAR)-T cell immunotherapies have showcased the potential of immuno-oncology in providing long-lasting treatments for cancer. This impact was felt in not just the CAR-T cell therapy […]

September 27, 2022 - 6 minutesmins - By Jonathan Smith

Using the power of proteomics to predict immunotherapy responses in melanoma and beyond

Next-generation proteomics has a vital role to play in the search for new biomarkers of immunotherapy response. Recent studies in melanoma presented at the European Society for Medical Oncology (ESMO) Congress highlight how these insights have the potential to transform cancer care. The recent success of immunotherapies that manipulate the patient’s immune system to recognize […]

September 27, 2022 - 6 minutesmins - By External Contributor

News and Trends 26 Sep 2022

TILT and MSD working on immunotherapy trial for non-small cell lung cancer

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA (pembrolizumab), MSD’s anti-PD-1 therapy. The […]

September 26, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 26 Sep 2022

Kupando raises €13M in series A funding round led by Remiges Ventures

A company developing agonists that stimulate immune cells today (September 26) announced it has secured €13 million ($12.6 million) in series A funding. Germany-based Kupando develops TLR/47 that stimulate innate immunity for use in oncology and infectious diseases. Kupando says it will use the funds to complete IND-enabling work and to initiate the clinical development […]

September 26, 2022 - 2 minutesmins - By Liza Laws

Startup Scout 22 Sep 2022

Cartography Biosciences unearths cancer immunotherapy targets

Despite its meteoric growth in the last twenty years, cancer immunotherapy research is hamstrung by a lack of viable drug targets. Cartography Biosciences is using a single-cell sequencing approach to meet this demand. Immuno-oncology as a field barely existed 20 years ago, but has rapidly grown into a thriving field of biotechnology research. This has […]

September 22, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 20 Sep 2022

Biopharma company Faron announces escalation data cancer treatment study

A clinical stage biopharma company has announced further dose escalation data from its phase 1/2 study looking at the safety and efficacy of a monotherapy in ten different hard-to-treat cancers. Latest progress from Faron Pharma’s MATINS (Macrophage Antibody To INhibit immune Suppression) study was focused on higher dose levels and frequencies to finalize the dose […]

September 20, 2022 - 4 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us